Third International Merkel Cell Carcinoma Conference

The Merkel Cell Carcinoma (MCC) conference is a dedicated platform designed to delve into the latest emerging data, shedding light on the fundamental biology driving this disease. It serves as a catalyst for refining clinical guidelines and cultivating innovative approaches to tackle MCC effectively. The conference showcases recent updates from clinical guidelines and highlights cutting-edge insights into MCC biology through its plenary sessions. Its overarching educational mission is to disseminate this evolving data widely, fostering a stimulating and collaborative environment to propel MCC research forward.

E-Poster Presentation

Purpose
The purpose of this meeting is to foster communication, interactions, and collaboration between people.  
In order to do this and to minimize the upfront work and cost to participants, we will be moving to a blend of electronic and verbal presentations as follows.

Digital Presentation
There will not be any physical poster boards.  Therefore, NO PHYSICAL POSTER is required.  
Instead, a bank of large electronic monitors will display the posters in the numerical order found within the meeting program brochure (also digitally available). These monitors will cycle through each individual poster presentation, displaying the entire list of abstract submissions repeatedly. These will be displayed throughout the length of the meeting.

Submission Format
Each submission will be in PowerPoint format and will consist of a total of 4 slides.
Authors have full discretion for their presentation however should include the following information.

-Slide One: Title of the Presentation, Authors and their titles, Affiliation, Funding source. Disclosures, contact information of the presenting author.
                Recommend Font:  Arial 16 or equivalent to allow readability 4 feet from screen.
-Slide Four (Final):  Conclusions
-Title slide is not required.

Given the small size and the highly specialized nature of this meeting, we aim to showcase many if not all the submissions through short 3 minute “Elevator Pitches” in the main lecture hall. Authors are asked to come prepared to give a short 3 minute verbal synopsis of their work.

Submission Deadline
Submit your e-poster presentation no later than April 19, 2024, via email to [email protected]

1. Demonstrate enhanced proficiency in Merkel Cell Carcinoma (MCC) management by integrating updated knowledge and strategies.
2. Apply evidence-based practices for optimal patient care in clinical settings.
3. Employ the latest advancements in Merkel Cell Carcinoma (MCC) management, demonstrating the ability to integrate emerging data and guidelines into clinical practice to improve patient outcomes.
4. Discuss how to effectively apply evolving guidelines and advancements in MCC treatment within clinical practice.

This one and a half day conference on Merkel Cell Carcinoma will begin on Friday, May 3, 2024, with Opening Remarks at 8:00 AM and will adjourn for the day at 6:00 PM.  The conference will reconvene on Saturday, May 4, 2024 at 8:00 AM and adjourn at 1:30 PM.   

This conference will be held at the Marriott Medical Center Hotel Houston, 6580 Fannin Street, Houston TX 77030. 

Advanced registration is encouraged as space is limited. 

If you are considering attending this conference, please follow the link below to create a profile in PEP prior to registering: https://mdanderson.cloud-cme.com/default.aspx

The deadline for advanced registration is Wednesday, April 24, 2024.

We accept the following forms of payment:

• Credit Cards (MasterCard, VISA, and American Express)

• Check made payable to: The University of Texas MD Anderson Cancer Center (payable through U.S. banks only)

Mail to: 
Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
 P.O. Box 301407
 Houston, Texas 77230-1407

Telephone registrations are not accepted.

When registering online a receipt (confirmation) will be automatically emailed to the e-mail address you list on the registration form.

Refund/Cancellation Policy
The registration fee, minus a $50.00 administration-handling fee, is refundable if a written request is received on or before Wednesday, April 17, 2024.  No refunds will be granted after these dates. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of Continuing Professional Education (CPE), reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary.  Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.  In case of activity cancellation, the liability of CPE, is limited to the registration fee.  CPE, will refund the full registration fee. 

CPE reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

For additional information, contact CPE, at 713-792-2223 or toll free at 866-849-5866 or via e-mail: [email protected].

Special Assistance
Contact CPE, at 713-792-2223 or toll free at 866-849-5866 if you have any ADA accommodation needs.

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

Merkel Cell Carcinoma Conference
Houston Marriott Medical Center/Museum District
6580 Fannin Street, Houston, TX 77030
T: 713.796.0080

Start Date: Thursday, May 2, 2024

End Date: Sunday, May 5, 2024

Last Day to Book at Group Rate of $159/night: Thursday, April 14, 2024

Group Code: MERMERR

Book your group rate for Merkel Cell Carcinoma Conference

Texas Medical Center (TMC) / Museum District Area Attractions

• Houston Zoo
• Hermann Park
• Miller Outdoor Theatre
• Japanese Garden
• Houston Museum of Natural Science
• The Museum of Fine Arts, Houston
• Children's Museum Houston
• Cockrell Butterfly Center

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Eric Gagneaux
Continuing Education Planner
MD Anderson Cancer Center

Activity Administrator

Non-Clinical Exception

Michael K Wong, MD, PhD, FRCPC
Physician in Chief
Roswell Park Comprehensive Cancer Center

Course Director, Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-EMD Serono Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Castle Biosciences, Inc.

Silvia Albertini, PhD
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany

Faculty

Nothing to disclose

Rashmi Bhakuni, PhD
Research Fellow
University of Washington School of Medicine

Faculty

Nothing to disclose

Shailender Bhatia, MBBS,MD
Professor
University of Washington

Faculty

Grant or research support-4SC|Honoraria-Bristol-Myers Squibb Company (Relationship has ended)|Honoraria-Incyte Corporation (Relationship has ended)|Other: Travel support-Regeneron Pharmaceuticals, Inc. (Relationship has ended)|Grant or research support-Agenus|Grant or research support-Amphivena|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Regeneron Pharmaceuticals, Inc.|Grant or research support-EMD Serono Inc.|Grant or research support-Exicure (Relationship has ended)|Grant or research support-Immune Design (Relationship has ended)|Grant or research support-Incyte Corporation|Grant or research support-Kuni Foundation|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Nektar Therapeutics (Relationship has ended)|Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-TriSalus Life Sciences|Grant or research support-Xencor

Andrew S Brohl, MD
Moffitt Cancer Center

Faculty

Nothing to disclose

Isaac Brownell, MD, PhD
Chief, Dermatology Branch
NIH

Faculty

Nothing to disclose

Sunandana Chandra, MD

Faculty

Advisor-Bristol-Myers Squibb Company|Advisor-Regeneron Pharmaceuticals, Inc. (Relationship has ended)|Advisor-Pfizer Inc. (Relationship has ended)|Advisor-Novartis Pharmaceuticals Corporation (Relationship has ended)|Advisor-Exicure (Relationship has ended)|Advisor-EMD Serono Inc. (Relationship has ended)

James DeCaprio, MD
Dana-Farber Cancer Institute

Faculty

Grant or research support-Kymera Therapeutics|Consulting Fee-Kymera Therapeutics|Consulting Fee-Mariana Oncology|Grant or research support-Rain Therapeutics (Relationship has ended)

Andrzej Dlugosz, MD
Professor
University of Michigan

Faculty

Nothing to disclose

Ecaterina E. Dumbrava, MD
Assistant Professor - Invest. Cancer Therapeutics
MD Anderson Cancer Center

Faculty

Advisor-BOLT Therapeutics|Advisor-Mersana|Advisor-Orum Therapeutics |Advisor-Summit Therapeutics |Grant or research support-Bayer HealthCare Pharmaceuticals, Inc.|Grant or research support-Immunocore LTD|Grant or research support-Amgen Inc.|Grant or research support-Aileron Therapeutics|Grant or research support-Compugen Ltd|Grant or research support-TRACON Pharmaceuticals Inc|Grant or research support- Unum Therapeutics|Grant or research support-Gilead Sciences, Inc.|Grant or research support-BOLT Therapeutics|Grant or research support-Aprea Therapeutics|Grant or research support-Bellicum Pharmaceuticals|Grant or research support-PMV Pharma |Grant or research support-Triumvira|Grant or research support-Seagen Inc|Grant or research support-Mereo BioPharma 5 Inc|Grant or research support-Sanofi|Grant or research support-Rain Oncology |Grant or research support-Astex Therapeutics |Grant or research support-Sotio|Grant or research support-Mersana Therapeutics|Grant or research support-Genentech|Grant or research support-Boehringer Ingelheim|Other: Consult (non-paid)-Catamaran Bio|Speakers Bureau-PMV Pharma |Other: Travel, Accommodations, Expenses-ASCO|Other: Travel, Accommodations, Expenses-LFSA Association |Other: Travel, Accommodations, Expenses-Rain Oncology |Other: Travel, Accommodations, Expenses-Banner MD Anderson Cancer Center

Denise Galloway, PhD
Professor
Fred Hutchinson Cancer Center

Faculty

Nothing to disclose

Berkley Gryder, PhD
Case Western Reserve School of Medicine

Faculty

Nothing to disclose

Sine Reker Hadrup, MD
Professor
Norwegian Univ of Science and Technology
Denmark

Faculty

Ownership-PokeAcell (Relationship has ended)|Royalties or Patent Beneficiary-immudex

Kelly Harms, MD, PhD
Dr.
University of Michigan

Faculty

Nothing to disclose

Paul Harms, MD, PhD
Michigan Medicine, University of Michigan

Faculty

Other: Efffort support for clinical trial correlatives-Certa Therapeutics (Relationship has ended)

Thibault Kervarrec, MD, PhD
Dr
University Hospital of Tours
France

Faculty

Nothing to disclose

David M Miller, MD, PhD
Mass General Brigham

Faculty

Consulting Fee-Bristol-Myers Squibb Company (Relationship has ended)|Paid consultant-Merck Sharp & Dohme Corp. (any division) (Relationship has ended)|Consulting Fee-Incyte Corporation (Relationship has ended)|Independent Contractor (included contracted research)-Kartos|Advisor-Checkpoint Therapeutics|Advisor-Avstera|Stocks or stock options, excluding diversified mutual funds-Checkpoint Therapeutics|Consulting Fee-Almirall|Consulting Fee-Regeneron Pharmaceuticals, Inc.|Independent Contractor (included contracted research)-NeoImmune Tech|Independent Contractor (included contracted research)-Xilios Therapeutics|Stocks or stock options, excluding diversified mutual funds-Avstera

Natalie J Miller, MD, PhD
Hematology and Medical Oncology Fellow
University of Washington/Fred Hutch Cancer Center

Faculty

Nothing to disclose

Paul Nghiem, MD, PhD
Professor
Univ of WA

Faculty

Grant or research support-Incyte Corporation

Victor G Prieto, MD, USCAP, ASDP, ISDP, CAP, ASCP
Chair and Professor
MD Anderson Cancer Center

Faculty

Consulting Fee-Myriad (Relationship has ended)|Consulting Fee-Orlucent|Consulting Fee-Castle Biosciences, Inc.

Thomas H Pulliam, PhD
Dr.
University of Washington

Faculty

Nothing to disclose

Zachary Zale Reinstein, BS
Northwestern University

Faculty

Nothing to disclose

Tobias Schatton, PharmD, PhD
Assistant Professor of Dermatology
Brigham and Women's Hospital

Faculty

Nothing to disclose

Ann W. Silk, MD
Dana-Farber Cancer Institute

Faculty

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Natera (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Illumina

Vernon K Sondak, MD
Chair
Moffitt Cancer Center

Faculty

Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Genesis Drug Discovery & Development|Consulting Fee-Helix Biopharma|Paid consultant-Iovance Biotherapeutics|Paid consultant-Merck Sharp & Dohme Corp. (any division)|Paid consultant-Mural Oncology|Paid consultant-Novartis Pharmaceuticals Corporation|Paid consultant-Sun Pharmaceuticals|Grant or research support-Neogene Therapeutics|Grant or research support-Skyline and Turnstone

Gabriel Starrett, PhD
Stadtman Investigator
National Cancer Institute

Faculty

Nothing to disclose

Kenneth Tsai, MD, PhD
H. Lee Moffitt Cancer Center & Research Institute

Faculty

Consulting Fee-NFlection Therapeutics |Independent Contractor (included contracted research)-Worldcare Clinical|Independent Contractor (included contracted research)-Verrica Pharmaceuticals

Cassian Yee, MD
MD Anderson Cancer Center

Faculty

Nothing to disclose

Phyu Aung, MD
Associate Professor
MD Anderson Cancer Center

Faculty, Other Planning Committee Member

Nothing to disclose

Devarati Mitra, MD
Assistant Professor
MD Anderson Cancer Center

Faculty, Other Planning Committee Member

Nothing to disclose

Merrick I. Ross, MD, FACS
Professor of Surgery
UT MD Anderson Cancer Center

Faculty, Other Planning Committee Member

Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Honoraria-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)

Asya Hayes, BA, Public Administration
Sr. Administrative Assistant
MD Anderson Cancer Center

Other Planning Committee Member

Nothing to disclose

Disclaimer: By clicking on "Exhibitors" you have left the accredited educational content of the course.

The conference organizing committee wishes to express appreciation to the following companies:

GOLD LEVEL

Website: https://www.regeneron.com/

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly translate science into medicine has led to numerous FDA-approved treatments and candidates in development. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, and through research initiatives such as the Regeneron Genetics Center. Visit www.Regeneron.com to learn more.

Social Media:
Facebook https://www.facebook.com/Regeneron/
Linkedin https://www.linkedin.com/company/regeneron-pharmaceuticals
Youtube https://www.youtube.com/c/Regeneron/

Product categories: Metastatic Disease, Clinical Trials, Drug Development, Human Genetics, Immunotherapy

BRONZE LEVEL

Website: https://www.merck.com/